Beyond cost considerations.
D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000068258:Bevacizumab; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D056687:Off-Label Use
D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab